{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:47:37Z","timestamp":1789681657937,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.gim.2024.101138","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T05:52:01Z","timestamp":1712555521000},"page":"101138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER"],"prefix":"10.1016","volume":"26","author":[{"given":"William R.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Abbruscato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Hornby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric M.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-9866","authenticated-orcid":false,"given":"Hilary J.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2024.101138_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpeds.2019.09.074","article-title":"A\u00a0bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population","volume":"217","author":"Miller","year":"2020","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.gim.2024.101138_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00246-022-02846-8","article-title":"Longitudinal observational study of cardiac outcome risk factor prediction in children, adolescents, and adults with Barth syndrome","volume":"43","author":"Chowdhury","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-019-1200-8","article-title":"Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study","volume":"14","author":"Mazar","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2024.101138_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1750-1172-8-23","article-title":"Barth syndrome","volume":"8","author":"Clarke","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2024.101138_bib5","series-title":"GeneReviews","first-page":"1","article-title":"Barth syndrome","author":"Ferreira","year":"1993"},{"key":"10.1016\/j.gim.2024.101138_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1750-1172-8-70","article-title":"Natural history of Barth syndrome: a national cohort study of 22 patients","volume":"8","author":"Rigaud","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/514886","article-title":"The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies","volume":"61","author":"D\u2019Adamo","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ng0496-385","article-title":"A\u00a0novel X-linked gene, G4.5. is responsible for Barth syndrome","volume":"12","author":"Bione","year":"1996","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jimd.12453","article-title":"Current and future treatment approaches for Barth syndrome","volume":"45","author":"Thompson","year":"2022","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.gim.2024.101138_bib10","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s10741-021-10177-8","article-title":"Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid","volume":"27","author":"Sabbah","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2217\/fca-2023-0008","article-title":"Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide","volume":"19","author":"Sabbah","year":"2023","journal-title":"Future Cardiol"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/ehjqcco\/qcx031","article-title":"New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome","volume":"4","author":"Bredy","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"10.1016\/j.gim.2024.101138_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10741-020-10031-3","article-title":"Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide","volume":"26","author":"Sabbah","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.gim.2024.101138_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.144148","article-title":"TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome","volume":"726","author":"Garlid","year":"2020","journal-title":"Gene"},{"issue":"51","key":"10.1016\/j.gim.2024.101138_bib15","doi-asserted-by":"crossref","first-page":"39217","DOI":"10.1074\/jbc.M606100200","article-title":"The enzymatic function of tafazzin","volume":"281","author":"Xu","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.gim.2024.101138_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101005","article-title":"Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules","volume":"297","author":"Anzmann","year":"2021","journal-title":"J\u00a0Biol Chem"},{"issue":"16","key":"10.1016\/j.gim.2024.101138_bib17","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14215","article-title":"SERCA2a tyrosine nitration coincides with impairments in maximal SERCA activity in left ventricles from tafazzin-deficient mice","volume":"7","author":"Braun","year":"2019","journal-title":"Physiol Rep"},{"issue":"6","key":"10.1016\/j.gim.2024.101138_bib18","article-title":"Restoration of mitochondrial cardiolipin attenuates cardiac damage in swine renovascular hypertension","volume":"5","author":"Eirin","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.gim.2024.101138_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206","article-title":"Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure","volume":"9","author":"Sabbah","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.gim.2024.101138_bib20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.gim.2024.101138_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCHEARTFAILURE.113.000406","article-title":"Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides","volume":"6","author":"Dai","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.gim.2024.101138_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/FJC.0000000000000155","article-title":"Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats","volume":"64","author":"Dai","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"8","key":"10.1016\/j.gim.2024.101138_bib23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.2012121216","article-title":"The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin","volume":"24","author":"Birk","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.gim.2024.101138_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fcvm.2019.00167","article-title":"SS-31 peptide reverses the mitochondrial fragmentation present in fibroblasts from patients with DCMA, a mitochondrial cardiomyopathy","volume":"6","author":"Machiraju","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s42003-020-1101-3","article-title":"The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats","volume":"3","author":"Allen","year":"2020","journal-title":"Commun Biol"},{"issue":"21","key":"10.1016\/j.gim.2024.101138_bib26","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1074\/jbc.RA119.012094","article-title":"The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a\u00a0key component of its mechanism of action","volume":"295","author":"Mitchell","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.gim.2024.101138_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","article-title":"A\u00a0phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism","volume":"23","author":"Reid Thompson","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13023-022-02469-5","article-title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome","volume":"17","author":"Hornby","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jimd.12425","article-title":"An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin\/cardiolipin ratio","volume":"45","author":"Vaz","year":"2022","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1164\/rccm.201212-2191ED","article-title":"The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease","volume":"187","author":"Holland","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.gim.2024.101138_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","article-title":"Clinically meaningful change estimates for the six-minute walk test and daily\u00a0activity in individuals with chronic heart failure","volume":"24","author":"Shoemaker","year":"2013","journal-title":"Cardiopulm Phys Ther J"},{"issue":"8","key":"10.1016\/j.gim.2024.101138_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1164\/rccm.202208-1547OC","article-title":"Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension","volume":"207","author":"Moutchia","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101138_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00246-015-1260-z","article-title":"Clinical characteristics and outcomes of cardiomyopathy in Barth syndrome: the UK experience","volume":"37","author":"Kang","year":"2016","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"10.1016\/j.gim.2024.101138_bib34","article-title":"Bendavia (MTP-131), a mitochondria targeting peptide, normalizes dysregulation of mitochondria fission and fusion proteins in myocardium of dogs with chronic heart failure","volume":"130","author":"Sabbah","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10557-018-6805-y","article-title":"Abnormalities of mitochondrial dynamics in the failing heart: normalization following long-term therapy with elamipretide","volume":"32","author":"Sabbah","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.gim.2024.101138_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1373\/clinchem.2007.095711","article-title":"Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome","volume":"54","author":"Kulik","year":"2008","journal-title":"Clin Chem"},{"issue":"14","key":"10.1016\/j.gim.2024.101138_bib37","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.gim.2024.101138_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcsm.12559","article-title":"A\u00a0randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy","volume":"11","author":"Karaa","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:39:12Z","timestamp":1720096752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360024000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1098360024000716"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2024.101138","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2024.101138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"101138"}}